Physician profile
John I Baron
NPI 1649263294
$4,688.89
in general payments reported to CMS, 2019-2025
26 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $385 · 2021: $546 · 2022: $641 · 2023: $745 · 2024: $686 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $842.11 | 2021-2025 | Verquvo, Capvaxive |
| Terumo Medical Corporation | $650.00 | 2019 | |
| Pfizer INC. | $501.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $421.14 | 2019-2024 | |
| Amgen INC. | $371.19 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.97 | 2020-2025 | Lifevest |
| Amarin Pharma, INC. | $268.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.31 | 2019-2022 | |
| Medtronic, INC. | $216.05 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $141.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.00 | 2020-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $69.36 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $61.26 | 2024-2025 | Nexletol |
| Abbott Laboratories | $55.98 | 2022-2024 | Gallant, Aveir |
| Lexicon Pharmaceuticals, INC. | $52.41 | 2023 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $51.47 | 2021-2023 | Zio Xt Patch |
| Impulse Dynamics (USA) INC. | $42.77 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $42.54 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $37.82 | 2019-2021 | |
| Lundbeck LLC | $37.45 | 2019-2020 | |
| Scpharmaceuticals INC. | $29.58 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $26.23 | 2024 | Arcalyst |
| Sanofi Pasteur INC. | $18.84 | 2023 | |
| Abiomed | $18.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.45 | 2022 | |
| Philips North America LLC | $14.24 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.